Exchange & Returns Information
Review Details
(0)
| Generic For | TAXOL |
|---|---|
| Active Ingredient | PACLITAXEL |
| Strength | 260MG |
| Manufacturer | BDR PHARMA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 34.80 | $ 34.80 |
$ 29.58
Apply ZARVY26 (-15%)
You save $ 5.22
|
||
| 2 BOXES - 2 VIALS | $ 32.00 |
8% $ 69.60
$ 64.00
|
$ 54.40
Apply ZARVY26 (-15%)
You save $ 9.60
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 31.93 |
8% $ 104.40
$ 95.80
|
$ 81.43
Apply ZARVY26 (-15%)
You save $ 14.37
|
Reference information will be available soon.
Bd-Taxel 260, Injection – 43.4 ml is an injectable chemotherapy formulation containing paclitaxel 260 mg, a potent cytotoxic antineoplastic agent derived from the Pacific yew tree.
Its mechanism of action is based on stabilizing microtubules, promoting their assembly and preventing disassembly. This disrupts the mitotic spindle apparatus, effectively halting cell division and inducing apoptosis in rapidly proliferating tumor cells.
The 260 mg high-dose formulation is administered according to body surface area (BSA) and is a key component of multiple chemotherapy protocols, serving as first-line, adjuvant, or salvage therapy.
Bd-Taxel 260 is widely used in the treatment of solid tumors such as:
Ovarian cancer
Breast cancer
Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)
By targeting microtubule dynamics, Bd-Taxel 260 remains a cornerstone chemotherapeutic agent in modern oncology for its precision and potent cytotoxic efficacy.
AntiCancer Drugs > Ovarian Cancer
Used as first-line or recurrent therapy for epithelial ovarian cancer, most often in combination with platinum agents. Demonstrates improved tumor shrinkage and survival rates in advanced-stage disease.
AntiCancer Drugs > Breast Cancer
Indicated for metastatic breast cancer after anthracycline failure, or as adjuvant therapy in early-stage node-positive disease. Provides enhanced outcomes when combined with trastuzumab in HER2-positive tumors.
AntiCancer Drugs > Non-Small Cell Lung Cancer (NSCLC)
Given with cisplatin in patients with inoperable or metastatic NSCLC to improve response rates and symptom control.
AntiCancer Drugs > Pancreatic Cancer
Combined with gemcitabine in metastatic pancreatic adenocarcinoma, showing improved median overall survival compared with gemcitabine alone.
AntiCancer Drugs > Cervical Cancer & Head and Neck Cancers
Applied in chemoradiation protocols or systemic therapy, particularly in unresectable or recurrent cases.
AntiCancer Drugs > Kaposi’s Sarcoma (AIDS-related)
Approved as second-line therapy for patients with HIV/AIDS-associated Kaposi’s Sarcoma, often administered with antiretroviral treatment.
Paclitaxel works by stabilizing microtubules and preventing their normal disassembly during mitosis. This disruption causes prolonged mitotic arrest, ultimately leading to apoptosis of tumor cells.
Because of its non–cell-cycle-specific activity, paclitaxel can effectively target rapidly dividing cancer cells at different phases of proliferation. It also demonstrates antiangiogenic properties, limiting tumor blood supply by reducing the formation of new blood vessels.
Importantly, paclitaxel has shown efficacy in multidrug-resistant cell lines, making it an especially valuable therapeutic choice in resistant or recurrent cancers where other treatments may fail.
Ovarian Cancer:
First-line: 175 mg/m² IV over 3 hours + cisplatin every 3 weeks
Alternative: 135 mg/m² IV over 24 hours + cisplatin every 3 weeks
Recurrent: 135–175 mg/m² IV over 3 hours every 3 weeks
Breast Cancer:
Metastatic: 175 mg/m² IV over 3 hours every 3 weeks
Adjuvant: 175 mg/m² IV over 3 hours every 3 weeks × 4 cycles (post-anthracycline)
Non-Small Cell Lung Cancer (NSCLC):
135 mg/m² IV over 24 hours + cisplatin every 3 weeks
Kaposi’s Sarcoma (AIDS-related):
135 mg/m² IV over 3 hours every 3 weeks
or 100 mg/m² IV over 3 hours every 2 weeks
Premedication Required:
Corticosteroids
H1 antagonists (e.g., diphenhydramine)
H2 blockers (e.g., ranitidine, famotidine)
→ All required to prevent hypersensitivity reactions
Dose Adjustments & Monitoring:
Withhold if ANC < 1000/mm³ or severe neuropathy occurs
Resume at 20% reduced dose after recovery
Consider G-CSF support for neutropenia management
Store below 25°C in the original carton to protect from light
Do not freeze
Diluted solutions should be used promptly or stored according to facility protocol
Inspect visually for particulates or discoloration before administration
Common side effects:
→ Neutropenia, anemia, leukopenia
→ Peripheral neuropathy, alopecia
→ Nausea, vomiting, mucositis, fatigue
Serious adverse effects:
→ Severe hypersensitivity reactions (including anaphylaxis)
→ Cardiac arrhythmias, bradycardia
→ Hepatotoxicity, pulmonary toxicity
→ Myelosuppression with risk of febrile neutropenia
Seek immediate medical attention for persistent fever, bleeding, chest pain, or difficulty breathing.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
